Wake Forest School of Medicine

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that the company will present new data on its 385-gene kidney genetic test, Renasight™ , at the annual meeting of the American Society of Nephrology (ASN) Kidney Week 2024. The meeting will take place in San Diego from Oct. 23-27. Natera and its collaborators will present 7 abstracts focused on comprehensive genetic testing for patients with chronic kidney disease (CKD). This includes an updated analysis from the prospective RenaCARE study , along with additional data on the utility of genetic testing for patients with CKD to enable more precise diagnoses, guide personalized treatment, and improve overall clinical outcomes. The evidence to be presented at ASN adds to growing support for renal genetic testing, including the recently updated Kidney Diseases Improving Global Outcomes (KDIGO) guideline for the management of CKD, a newly published consensus statement on renal genetics by The National Kidney Foundation (NKF), 1,2 and a review article published in The New England Journal of Medicine 3 reiterating the clinical utility of genetic testing for the majority of patients with CKD. “This has been a pivotal year in the field of renal genetic testing, with robust and unified support coming from leading organizations like NKF, KDIGO, and the New England Journal of Medicine on the benefits of comprehensive genetic testing for patients with CKD,” said Anthony Bleyer, MD, MS, professor of nephrology at Wake Forest University School of Medicine. “The reality is that 25% of patients on dialysis do not know the cause of their kidney disease and they have a right to know what is causing their disease and know the resources available for their specific condition.” “We are pleased to present data with our collaborators at ASN that further supports the clinical need for testing alongside these recent recommendations and guideline updates,” said Maggie Westemeyer, MS, CGC, director of clinical genetic services for Organ Health at Natera. The full list of presentations at ASN Kidney Week include: Poster Presentation | Abstract # TH-PO526 | Presenter: Meg Hager, MS, MPH, CGC | October 24, 10:00 AM to 12:00 PM PT | Renasight Patient Satisfaction and Outcomes Following a Session with a Genetic Counselor for Kidney Disease Poster Presentation | Abstract # FR-PO653 | Presenter: Anthony Bleyer, MD, MS | October 25, 10:00 AM to 12:00 PM PT | Renasight Results of Genetic Testing with a 385-Gene Panel in African American Patients with Kidney Disease Poster Presentation | Abstract # FR-PO655 | Presenter: Insa Schmidt, MD, MPH | October 25, 10:00 AM to 12:00 PM PT | Renasight Genetic testing in biopsy-confirmed kidney disease Poster Presentation | Abstract # FR-PO658 | Presenter: Maggie Westemeyer, MS, CGC | October 25, 10:00 AM to 12:00 PM PT | Renasight The RenaCARE Study: Updating Genetic Testing Results in Response to New Gene-Disease Association and Variant Upgrade Poster Presentation | Abstract # FR-PO659 | Presenter: Maggie Westemeyer, MS, CGC | October 25, 10:00 AM to 12:00 PM PT | Renasight Fabry Disease Genetic Diagnosis in a Large CKD Population Tested with a Broad Renal Gene Panel Poster Presentation | Abstract # FR-PO667 | Presenter: Michelle Bloom, PhD | October 25, 10:00 AM to 12:00 PM PT | Renasight The Genetic Landscape of Glomerular Disease and FSGS among >50,000 Genetically Tested for CKD Poster Presentation | Abstract # SA-PO578 | Presenter: Dinah Clark, MS, CGC | October 26, 10:00 AM to 12:00 PM PT | Renasight Assessment of Key Indicators of Pathogenicity in PKD1/2 Variants About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 200 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit . Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in “Risk Factors” in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and . References KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Stevens, P E, et al. Kidney International. 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018 Advancing Genetic Testing in Kidney Diseases: Report from a National Kidney Foundation Working Group. Franceschini, N, et al. American Journal of Kidney Diseases . 2024; doi:10.1053/j.ajkd.2024.05.010 Vivante A. Genetics of Chronic Kidney Disease. New England Journal of Medicine . 2024;391(7):627-639. doi:10.1056/NEJMra2308577 Contacts Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-405-4709, investor@natera.com Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

– Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases – – Cardiovascular Scientific Advisory Board expected to provide strategic guidance as Tourmaline advances pacibekitug towards potential Phase 3 clinical trial readiness in 2025 for the treatment of cardiovascular diseases – NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the formation of its Cardiovascular Scientific Advisory Board (CV SAB). The CV SAB is expected to provide strategic guidance and expertise as Tourmaline advances its pacibekitug cardiovascular diseases program, including the TRANQUILITY Phase 2 clinical trial that commenced earlier this year and for which Tourmaline continues to expect topline data in the first half of 2025. The CV SAB brings together academic and industry veterans with significant experience in cardiovascular medicine, clinical trial design and execution, and therapeutic innovation. Their insights and guidance are expected to be instrumental in shaping the strategic direction of Tourmaline’s cardiovascular program as the company prepares for Phase 3 clinical trial readiness in 2025, supporting efforts to redefine standards of care for high-risk cardiovascular disease patients. Cardiovascular Scientific Advisory Board Members: Joshua Beckman, MD, MSc – UT Southwestern Medical CenterMarc Bonaca, MD, MPH – University of Colorado, CPC Clinical ResearchRobin Choudhury, MA, DM, FRCP – University of OxfordDouglas L. Mann, MD – Washington University School of MedicineJames Min, MD – Cleerly, Inc.Pradeep Natarajan, MD, MMSc – Massachusetts General HospitalMichael D. Shapiro, DO, MCR – Wake Forest University School of MedicineMichael Szarek, PhD – University of Colorado, CPC Clinical Research “We are honored to welcome such a distinguished group of experts to our Cardiovascular Scientific Advisory Board,” said Emil deGoma, MD, Senior Vice President of Medical Research at Tourmaline. “The depth and breadth of their collective expertise across atherosclerotic cardiovascular disease (ASCVD), heart failure, vascular medicine, imaging, genetics, and biostatistics will be invaluable as we advance pacibekitug for cardiovascular diseases. A growing body of evidence continues to support the therapeutic potential of IL-6 inhibition in ASCVD and beyond.” For more information about Tourmaline Bio and pacibekitug, please visit https://www.tourmalinebio.com. About Tourmaline BioTourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006). About Pacibekitug Pacibekitug (also referred to as TOUR006) is a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. Pacibekitug has been previously studied in approximately 450 participants, including patients with autoimmune disorders, across six completed clinical trials. Tourmaline is developing pacibekitug in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional diseases under consideration. Cautionary Note Regarding Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “believe,” “designed to,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions, and are based on Tourmaline’s current beliefs and expectations. These forward-looking statements include expectations regarding the development and potential therapeutic benefits of pacibekitug; the timing of initiation, progress and results of Tourmaline’s current and future clinical trials for pacibekitug, including reporting of data therefrom; the timing of Phase 3 clinical trial readiness; and the timing and potential to expand pacibekitug into additional indications. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of therapeutic product candidates, such as the risk that any one or more of Tourmaline’s current or future product candidates will not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Tourmaline’s current or future product candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Tourmaline’s current or future product candidates; the risk that Tourmaline’s current or future product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that Tourmaline anticipates; risks regarding the accuracy of Tourmaline’s estimates of expenses, capital requirements and needs for additional financing; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; unexpected litigation or other disputes; the impacts of macroeconomic conditions Tourmaline’s business, clinical trials and financial position; and other risks and uncertainties that are described in Tourmaline’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (“SEC”) on August 8, 2024 and other filings that Tourmaline makes with the SEC from time to time. Any forward-looking statements speak only as of the date of this press release and are based on information available to Tourmaline as of the date hereof, and Tourmaline assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. Media ContactScient PRSarah MishekSMishek@ScientPR.com Investor ContactMeru AdvisorsLee M. Sternlstern@meruadvisors.com

Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD populationLONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces four oral presentations and two posters on analyses from its successful Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (“COPD”) will be presented at CHEST Annual Meeting (“CHEST”) 2024. The analyses are published in the CHEST Annual Meeting on-line supplement. Ohtuvayre (ensifentrine) is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase three and phosphodiesterase 4 (“PDE3 and PDE4”) that combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule. Ohtuvayre is the first novel inhaled mechanism for the maintenance treatment of COPD in more than 20 years. The analyses will summarize the efficacy and safety of Ohtuvayre in subgroups of COPD patients including data supporting improvements in lung function, symptoms and quality of life, as well as reductions in the rate of exacerbations, regardless of COPD severity (moderate or severe), smoking status (current or former), and chronic bronchitis (with or without). Furthermore, an analysis of ensifentrine’s impact on reducing exacerbation rates and COPD-related healthcare resource utilization over 48 weeks will also be presented. “Ensifentrine is a remarkable addition to COPD therapy,” said William Stringer, MD, FCCP, Professor of Medicine in the David Geffen School of Medicine at UCLA. “It has the capacity to bronchodilate, reduce inflammation, augment mucociliary clearance, and reduce exacerbations in smokers and former smokers.” Details of Verona Pharma’s presentations and posters are listed below and linked to the CHEST website. In addition, the Company will present five presentations that will highlight the unmet need in COPD based on real world claims data. Oral presentation: Ensifentrine improved lung function, symptoms, and quality of life regardless of COPD severityPresenter: Jessica Bon, MD, Wake Forest University School of MedicineSession: Assessing Treatment Outcomes in Obstructive Lung Disease Oral presentation: Ensifentrine, a novel COPD treatment, reduced COPD-related healthcare resource utilization over 48 weeksPresenter: Emily Wan, MD, Brigham and Women’s Hospital and Harvard Medical SchoolSession: Emerging Treatments in Obstructive Lung Disease Oral presentation: Ensifentrine improved lung function in patients with moderate to severe COPD: a pooled analysis from the Phase 3 ENHANCE trialsPresenter: Diego J. Maselli Caceres, MD, FCCP, Division of Pulmonary Diseases and Critical Care, UT Health San AntonioSession: Emerging Treatments in Obstructive Lung Disease Oral presentation: Ensifentrine improved lung function and reduced exacerbation rate and risk in patients with COPD regardless of smoking statusPresenter: Amy Dixon, PharmD, Verona PharmaSession: Novel Therapeutic Targets and Interventions in Obstructive Lung Disease Poster 3513: Ensifentrine improved symptoms and quality of life in patients with moderate-to-severe COPD regardless of smoking statusPresenter: William Stringer, MD, FCCP, David Geffen School of Medicine at UCLASession: Novel Therapeutic Targets and Interventions in Obstructive Lung Disease Poster 4285: Ensifentrine improved symptoms and quality of life in patients with COPD regardless of bronchitis historyPresenter: Jill Ohar, MD, Wake Forest University School of MedicineSession: Lung Disease Abstracts Posters For further information please contact: Verona Pharma plcTel: +1-844-341-9901Victoria Stewart, Senior Director of InvestorRelations and CommunicationsIR@veronapharma.comArgot Partners(US Investor Enquiries)Tel: +1-212-600-1902verona@argotpartners.comTen Bridge CommunicationsInternational / US Media EnquiriesTel: +1-312-523-5016tbcverona@tenbridgecommunications.comLeslie Humbel About Ohtuvayre (ensifentrine) Ohtuvayre is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Verona has evaluated nebulized Ohtuvayre in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Ohtuvayre met the primary endpoint in both ENHANCE-1 and ENHANCE-2, demonstrating statistically significant and clinically meaningful improvements in lung function. A fixed-dose combination of ensifentrine and glycopyrrolate, a LAMA, is currently under development for the maintenance treatment of COPD. About Verona Pharma Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements. Words such as “anticipate,” “believe,” “plan,” “expect,” “intend,” “may,” “potential,” “prepare,” “possible” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the potential benefits and efficacy of our drug Ohtuvayre and future poster presentations and academic publications pertaining to Ohtuvayre. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the efficacy of Ohtuvayre compared to competing drugs and the other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended June 30, 2024 filed with the Securities and Exchange Commission (“SEC”) on August 8, 2024, as such factors may be updated from time to time in our other filings with the SEC. We disclaim any obligation to update or revise any forward-looking statement contained in this press release, even if subsequent events cause our views to change, except as required under applicable law.